How can MRD assessment help when treating patients with high-risk MM after transplantation?

During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the Multiple Myeloma Hub was pleased to speak to Elena Zamagni, University of Bologna, Bologna, IT. We asked, How can MRD assessment help when treating patients with high-risk MM after transplantation?

In this video, Zamagni discusses how high-risk patients are treated the same as low/medium-risk patients, and can achieve a good response. Zamagni then talks about recent trials, including the MASTER trial, which highlights the difficulties faced by high-risk patients in maintaining MRD negativity. Finally, Zamagni discusses how consolidation therapy and better MRD monitoring could benefit high-risk patients.